Summary by Moomoo AI
Virpax Pharmaceuticals, Inc. has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC) on April 5, 2024. The filing is intended to register an additional 46,853 shares of common stock under the company's 2022 Equity Incentive Plan. This includes an automatic increase of 23,428 shares as of January 1, 2023, and a further increase of 23,425 shares as of January 1, 2024, as per the plan's evergreen provision. The newly registered shares are of the same class as those in the prior registration statement filed on November 11, 2022. The company, headquartered in Berwyn, Pennsylvania, has incorporated by reference its latest annual report and other recent filings with the SEC. The registration also includes documents such as the company's amended and restated certificate of incorporation, bylaws, and various forms of equity incentive agreements.